Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre

Table 1

Clinical and pathological features of patients who underwent sentinel lymph node biopsy (SLNB) between 2004 and 2010 by SLN status and univariable association with positive SLN.

	Total; 𝑁 (%)/mean (±SD)	SLN negative 𝑁 (%)/mean (±SD)	SLN positive 𝑁 (%)/mean (±SD)	𝑃 value	OR (95% CI)
Number of patients	221	173 (78.3)	48 (21.7)
Age, yr	59.3 (±15.9)	58.8 (±16.4)	60.0 (±14.0)	NS
Gender
Female	136 (61.5)	116 (85.3)	20 (14.7)	<0.001	2.85 (1.48–5.49)
Male	85 (38.5)	57 (67.1)	28 (32.9)
Tumor location
Head and neck	23 (10.5)	20 (87)	3 (13)	NS
Upper limb	33 (15)	30 (90.9)	3 (9.1)
Lower limb	95 (43)	70 (73.7)	25 (26.3)
Trunk	69 (31.4)	52 (75.4)	17 (24.6)
Histologic type
Superficial spreading	38 (17.2)	35 (92.1)	3 (7.9)	0.001
Nodular	45 (20.4)	30 (66.7)	15 (33.3)
Acral lentiginous	47 (21.3)	30 (63.8)	17 (36.2)
Unknown/others (spitzoid, desmoplastic, nevoid, amelanotic)	91 (41.2)	78 (85.7)	13 (14.3)
Breslow (mean, mm)	3.08 (±2.88)	2.60 (±3.88)	4.74 (±2.32)	<0.001
Breslow category
T1 (≤1 mm)	21 (10)	20 (95.2)	1 (4.8)	<0.001
T2 (1.01–2 mm)	89 (42.4)	79 (88.8)	10 (11.2)
T3 (2.01–4 mm)	57 (27.1)	41 (71.9)	16 (28.1)
T4 (≥4 mm)	43 (20.5)	23 (53.5)	20 (46.5)
Ulceration
Absent	97 (53.3)	79 (81.4)	18 (18.6)	NS
Present	85 (46.7)	60 (70.6)	25 (29.4)
Tumor-infiltrating lymphocytes
Present	80 (60.2)	69 (86.3)	11 (13.8)	0.021	2.71 (1.42–6.44)
Absent	53 (39.8)	37 (69.8)	16 (30.2)
SLN site
Axilla	92 (41.8)	72 (78.3)	20 (21.7)	NS
Inguinal	100 (45.5)	75 (75)	25 (25)
Cervical	28 (12.7)	25 (89.3)	3 (10.7)

NS: not statistically significant; CI: confidence interval.